ClinicalTrials.gg
RecruitingNCT07938697Updated Nov 16, 2026

Development and Testing of a Brief Tool to Assess Breakthrough Cancer Pain in Taiwan

A Phase 4 interventional study of Fentanyl buccal soluble film in Breakthrough Cancer Pain, sponsored by Chang Gung Memorial Hospital. Recruiting at 4 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Chang Gung Memorial Hospital · Phase 4, Interventional, and Other

From the registry’s dates

  • Registered 3 years 3 months after the study started (first participant enrolled Aug 2023, registered Nov 2026).
  • Started Aug 2023; still recruiting 3 years 3 months later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,073
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Cancer Pain with a site in Taiwan — 4 open to participants now, 4 under way, none of them phase 3. Cancer Pain · Taiwan.

Planned enrollment
Largest of 14
1,073 · median 89
Started
2023
the only one that year
Phase 4
3 of 19
1 open now
Registered
19th of 19
by date
Lead sponsor
4 of 19
Chang Gung Memorial Hospital

Among the 19 studies in Cancer Pain with a site in Taiwan, this one has the largest planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 4, and was the 19th registered.

Cancer Pain

311 studies on the registry are indexed under Cancer Pain; 74 are open to participants now.

Browse Cancer Pain studies →

Open to participants now

4 of the 19 studies in Cancer Pain with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 44 Cancer Pain studies recruiting now, 32 (73%) set no upper age limit and 4 (9%) stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Cancer Pain with a site in Taiwan, or all of them as a file.
02

Study summary

This study aims to develop and test a brief tool called the Breakthrough Cancer Pain Assessment (BCPA) for use with cancer patients in Taiwan. The tool is intended to help medical staff assess episodes of breakthrough cancer pain in busy clinical settings.

The study has three stages. First, 14 clinical experts will review an initial set of 11 questions and assess whether they are relevant and important. Second, two medical staff members will separately interview each of 30 patients within three hours on the same day and independently record the answers to evaluate agreement between their ratings. Third, the tool will be applied in 1,043 patients recruited from multiple hospitals who are receiving short-acting opioids other than Painkyl.

In the clinical application stage, physicians will prescribe and individually adjust fentanyl buccal soluble film (Painkyl) for patients whose breakthrough pain is not meaningfully relieved within 15 minutes or whose medication administration route needs adjustment. These patients will be reassessed with the BCPA one to two weeks later. Patients with satisfactory pain relief at the initial assessment will undergo no further study procedures.

The main objectives are to evaluate the content validity and inter-rater reliability of the BCPA. A secondary objective is to determine the percentage of patients reporting meaningful pain relief within or at 15 minutes after taking Painkyl.

The planned secondary assessments also compare the pretreatment and post-treatment percentages of patients reporting meaningful pain relief within 15 minutes and their usual breakthrough pain intensity. Relief is reported by the patient using BCPA item 9; pain intensity is assessed using BCPA item 6 on a 0-to-10 scale.

Read the detailed description

The protocol describes an open-label, multicenter study comprising tool development, inter-rater reliability testing, and clinical application of the Breakthrough Cancer Pain Assessment (BCPA).

An initial set of 11 items will be developed from the literature and the opinions of oncologists experienced in managing breakthrough cancer pain. Fourteen experts in breakthrough cancer pain and/or pain instrument development will rate item relevance and importance using a four-point scale. Experts will provide comments on items rated as not or somewhat relevant or important. A Delphi process, with a maximum of four rounds, will provide feedback on item ratings and content validity. Items may be modified or deleted based on the expert review. The Delphi assessment period was approximately one month.

For inter-rater reliability testing, two medical staff members will separately interview each of 30 patients from one study site within three hours on the same day and independently record the answers. Items with low agreement or consistency will be discussed and revised before clinical application.

The clinical application stage will recruit 1,043 patients from multiple hospitals who are receiving short-acting opioids other than Painkyl. The BCPA will be used at the initial assessment to evaluate breakthrough pain control. Patients with satisfactory pain relief will undergo no further study procedures. Patients with unsatisfactory control, defined as taking more than 15 minutes to achieve meaningful relief with their current breakthrough pain medication other than Painkyl, and/or requiring a change in medication administration route at the physician's discretion, will receive Painkyl with individual dose titration and education on its use. The protocol schedules the pretreatment assessment on Day 0-1, treatment initiation on Day 1, and reassessment on Day 8-15.

The research nurse will check completed BCPA questionnaires to minimize missing data. The protocol defines a full analysis set requiring at least one BCPA assessment and an evaluable-patient set requiring both pretreatment and post-treatment assessments, in addition to informed consent, eligibility, and no protocol violations.

BCPA Tool V1.2 (14-Apr-2023) item 9 asks the patient how long rescue medication takes to provide effective pain relief. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, indicate meaningful relief within 15 minutes. Responses of no effect or more than 15 minutes indicate that this criterion is not met. Pretreatment responses concern the existing rescue medication; post-treatment responses concern Painkyl. BCPA item 6 assesses usual breakthrough pain intensity on a 0-to-10 numeric scale, where 0 is no pain and 10 is the worst pain. Higher scores indicate greater pain intensity. The questionnaire does not specify a fixed recall period.

The protocol specifies a Cochran Q test to compare pretreatment and post-treatment meaningful-relief percentages and generalized estimating equations (GEE) to examine pretreatment and post-treatment pain intensity. These analyses supplement the post-treatment meaningful-relief percentage.

03

Conditions studied

  • Breakthrough Cancer Pain

Browse trials for

Keywords

  • Breakthrough cancer pain
  • Cancer pain
  • Content validity
  • Inter-rater reliability
  • Breakthrough Cancer Pain Assessment
  • Fentanyl buccal soluble film
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged 18 years or older.
  • Breakthrough pain occurring on at least two days during the preceding two weeks, with no more than three episodes per day.
  • Opioid-tolerant patients with cancer who have received at least 60 mg/day of oral morphine equivalents for one week.

Additional Inclusion Criterion for the Clinical Application Stage (Stage 3):

- Patients must be receiving short-acting opioids other than Painkyl.

Exclusion criteria

Exclusion Criteria:

  • High risk of opioid-induced respiratory depression, in the investigator's judgment.
  • Considered unsuitable for participation by the investigator.
  • Known pregnancy or breastfeeding.
  • Previous use of fentanyl buccal soluble film (Painkyl).
  • History of or intolerance to fentanyl.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,073 participants (estimated)

Study arms

  • Experimental
    BCPA-guided assessment and Painkyl treatment

    In the clinical application stage, patients receiving short-acting opioids other than Painkyl undergo BCPA assessment. Those with unsatisfactory breakthrough pain control and/or requiring a change in medication administration route receive individually titrated Painkyl and a follow-up BCPA assessment. Patients with satisfactory pain relief at the initial assessment undergo no further study procedures. There is no comparator arm. The preceding tool-development stage includes a separate group of 30 patients. Two medical staff members separately interview each patient within three hours on the same day and independently record the answers for inter-rater reliability testing.

    Drug: Fentanyl buccal soluble film

Interventions

  • Fentanyl buccal soluble film (Painkyl) will be used for breakthrough cancer pain in patients whose current medication does not provide meaningful relief within 15 minutes and/or whose medication administration route requires adjustment. The dose will be individually titrated by the physician, starting at 200 mcg. The protocol specifies a maximum dose of 1,200 mcg per breakthrough pain episode. Patients will receive education on proper use and will be reassessed with the BCPA one to two weeks later.

    Also known as: Painkyl

06

What researchers measure

Primary outcomes

  1. Item-Level Content Validity Index of the BCPA

    The item-level content validity index (I-CVI) is the proportion of the 14 experts who rate a BCPA item as 3 (quite relevant) or 4 (highly relevant) on a four-point relevance scale. I-CVI will be calculated for each item during the Delphi process. Values range from 0 to 1, with higher values indicating greater expert agreement on item relevance.

    Time frame: At each Delphi round during an assessment period of approximately one month (maximum of four rounds).

  2. Scale-Level Content Validity Indices of the BCPA

    Two scale-level content validity indices will be calculated for the final tool: S-CVI/Ave, the average of the item-level content validity indices, and S-CVI/UA, the proportion of items rated as 3 or 4 by all experts. Both indices range from 0 to 1, with higher values indicating greater content validity.

    Time frame: At completion of the Delphi content-validation process, approximately one month after the first round (maximum of four rounds).

  3. Inter-Rater Agreement for Categorical BCPA Items

    Kappa will be calculated for each categorical BCPA item to assess agreement between ratings in 30 patients. Two medical staff members separately interview the same patient within three hours on the same day and independently record the answers.

    Time frame: Day 1; the two independent assessments are completed within three hours.

  4. Inter-Rater Consistency for Continuous BCPA Items

    Intraclass correlation coefficients will be calculated for continuous BCPA items to assess consistency between ratings in 30 patients. Two medical staff members separately interview the same patient within three hours on the same day and independently record the answers.

    Time frame: Day 1; the two independent assessments are completed within three hours.

Secondary outcomes

  1. Percentage of Patients With Meaningful Pain Relief Within or at 15 Minutes After Painkyl Administration

    Patient-reported meaningful relief is assessed using BCPA Tool V1.2 item 9, which asks how long rescue medication takes to provide effective pain relief. At the post-treatment assessment, the medication is Painkyl. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, meet the endpoint. Responses of no effect or more than 15 minutes do not meet it. The percentage is the number of patients meeting the endpoint divided by the number of patients who received Painkyl, multiplied by 100.

    Time frame: At the post-treatment BCPA assessment on Day 8-15, assessing meaningful pain relief within or at 15 minutes after Painkyl administration.

  2. Change in the Percentage of Patients Reporting Meaningful Pain Relief Within 15 Minutes From Pretreatment to Post-treatment

    The pretreatment and post-treatment percentages of patients reporting meaningful pain relief within 15 minutes will be compared using BCPA Tool V1.2 item 9. Responses of 10 minutes or less, or more than 10 but no more than 15 minutes, meet the relief criterion; no effect or more than 15 minutes does not. Pretreatment responses concern the existing rescue medication other than Painkyl; post-treatment responses concern Painkyl. The protocol defines evaluable patients as those with both pretreatment and post-treatment BCPA assessments, informed consent, eligibility, and no protocol violations. The protocol specifies a Cochran Q test for this comparison.

    Time frame: Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.

  3. Change From Pretreatment to Post-treatment in Usual Breakthrough Pain Intensity

    Usual breakthrough pain intensity is assessed using BCPA Tool V1.2 item 6: how painful the patient's breakthrough pain usually is. Patients select an integer from 0 to 10, where 0 means no pain and 10 means the worst pain; higher scores indicate greater pain intensity. Pretreatment and post-treatment scores will be compared. The questionnaire does not specify a fixed recall period. The protocol defines evaluable patients as those with both pretreatment and post-treatment BCPA assessments, informed consent, eligibility, and no protocol violations, and specifies generalized estimating equations (GEE) to examine the difference in pain intensity.

    Time frame: Pretreatment BCPA assessment on Day 0-1 and post-treatment BCPA assessment on Day 8-15.

07

Study locations

4 of 4 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2023 to primary completion in Sep 2023, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartActual
Aug 1, 2023
Primary completionActual
Sep 20, 2023
CompletionEst.
Feb 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07938697
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Aug 1, 2023
Primary completion
Sep 20, 2023
Completion
Feb 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Pei-Hung Chang
Contact
ph555chang@cgmh.org.tw
+886-2-24329292 ext. 2360
Cheng-Hsu Wang
principal investigator · Chang Gung Memorial Hospital, Keelung

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fentanyl Buccal Soluble Film

Start the discussion